Table 2.
Measures of cardiometabolic health. HOMA-IR, Homeostatic model assessment for insulin resistance; TGs, triglycerides; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure. * indicates different from baseline, p ≤ 0.05.
| Variable | Group | Baseline | 4 Week | 8 Week | 16 Week | p Value |
|---|---|---|---|---|---|---|
| glucose (mg/dL) | placebo | 92.3 ± 4.1 | 93.8 ± 3.7 | 92.9 ± 3.9 | 94.4 ± 3.2 | 0.656 |
| MSM | 92.5 ± 3.0 | 95.0 ± 2.8 | 93.8 ± 2.9 | 93.2 ± 2.5 | ||
| insulin (uUI/mL) | placebo | 19.6 ± 3.6 | 18.2 ± 4.4 | 17.4 ± 5.4 | 20.6 ± 5.8 | 0.097 |
| MSM | 18.5 ± 2.6 | 18.3 ± 1.7 | 14.7 ± 1.5 | 17.9 ± 1.6 | ||
| HOMA-IR | placebo | 4.5 ± 0.8 | 4.2 ± 1.1 | 4.0 ± 1.3 | 4.8 ± 1.4 | 0.260 |
| MSM | 4.2 ± 0.6 | 4.3 ± 0.4 | 3.9 ± 0.5 | 4.1 ± 0.4 | ||
| Total Cholesterol (mg/dL) | placebo | 188.3 ± 11.5 | 194.3 ± 8.0 | 200 ± 9.4 | 186.9 ± 9.3 | 0.099 |
| MSM | 172.2 ± 10.3 | 179.0 ± 8.4 | 181.2 ± 8.0 | 176.4 ± 8.3 | ||
| TGs (mg/dL) | placebo | 165.0 ± 36.0 | 121.1 ± 13.8 | 156.4 ± 35.7 | 162.1 ± 26.2 | 0.515 |
| MSM | 112.5 ± 11.4 | 110.7 ± 9.6 | 112.1 ± 12.8 | 131.6 ± 18.3 | ||
| LDL (mg/dL) | placebo | 118.6 ± 9.2 | 123.9 ± 6.5 | 127.6 ± 9.7 | 109.7 ± 10.2 | 0.126 |
| MSM | 102.0 ± 8.5 | 106.2 ± 7.3 | 107.4 ± 5.6 | 100.2 ± 6.3 | ||
| VLDL (mg/dL) | placebo | 27.8 ± 3.4 | 24.4 ± 2.7 | 27.1 ± 1.4 | 29.2 ± 5.2 | 0.235 |
| MSM | 22.5 ± 2.3 | 22.2 ± 1.9 | 21.6 ± 2.6 | 24.4 ± 3.6 | ||
| HDL (mg/dL) | placebo | 42.7 ± 2.5 | 46.0 ± 3.8 | 46.3 ± 3.8 | 48.0 ± 4.9 | 0.003 |
| MSM | 44.9 ± 3.7 | 50.7 ± 3.0 | * 52.2 ± 2.9 | * 51.8 ± 2.8 | ||
| SBP (mmHg) | placebo | 123.5 ± 5.2 | 118.1 ± 5.2 | 119.3 ± 5.4 | 114.9 ± 3.1 | 0.625 |
| MSM | 127.3 ± 4.6 | 120.3 ± 5.2 | 119.7 ± 4.0 | 121.6 ± 4.8 | ||
| DBP (mmHg) | placebo | 84.8 ± 4.5 | 77.6 ± 3.5 | 79.8 ± 3.0 | 78.2 ± 2.6 | 0.967 |
| MSM | 80.7 ± 3.1 | 81.3 ± 4.0 | 77.6 ± 3.5 | 80.1 ± 3.3 |